Science & academia

This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.

Industrial pipes and infrastructure at a coastal energy facility for an article about carbon capture and storage, for article on fusion plasma record, for article on fusion plasma record, for article on fusion endurance record, for article on nuclear fusion ignition

China sets new fusion endurance record of over a thousand seconds

By / / Good News For Humankind

Fusion energy took a real step forward this month: a reactor in China held superheated plasma stable for 1,066 seconds — more than 17 minutes, and over double the 403-second record the same machine set in 2023. The Experimental Advanced Superconducting Tokamak in Hefei pulled it off after engineers doubled the system’s power output while keeping the reaction from collapsing, which is the hardest part of fusion research. Sustained stability like this is exactly what a future fusion plant would need to actually generate continuous electricity. Findings from EAST will also feed directly into ITER, the massive international reactor rising in southern France. It’s a reminder that the dream of clean, nearly limitless energy is being built one patient breakthrough at a time.

A medical researcher reviewing cancer treatment data in a laboratory, for an article about breast cancer immunotherapy

Australian researchers nearly double cure rates for the most common breast cancer

By / / Good News For Humankind

Breast cancer immunotherapy has achieved a breakthrough in Australia, with researchers nearly doubling cure rates for hormone receptor-positive breast cancer — the most common form of the disease, representing roughly 70% of all diagnoses worldwide. A combination of immunotherapy and chemotherapy produced pathological complete responses, meaning no detectable cancer remained at surgery, at rates far exceeding historical norms below 20%. Because HR+ tumors have long resisted immunotherapy, this result marks a significant turning point. With over 2.3 million breast cancer cases diagnosed globally each year, most of them HR+, the potential scale of impact is enormous.

Depiction of intestines, for article on dostarlimab FDA breakthrough designation, for article on dostarlimab FDA Breakthrough Designation

“100% successful” cancer drug gets landmark U.S. FDA approval

By / / Good News For Humankind

A cancer drug called dostarlimab just earned the FDA’s Breakthrough Therapy Designation after eliminating rectal tumors in all 42 patients who completed a Memorial Sloan Kettering trial — with some participants now cancer-free for up to four years. The drug works by helping the immune system recognize and attack tumors carrying a specific genetic signature, sparing patients the surgery, radiation, and chemotherapy that often leave lasting damage to fertility, bowel function, and quality of life. Side effects have been mild, and the new designation could shave years off the path to wider availability. For the roughly 46,220 Americans diagnosed with rectal cancer each year, this hints at a future where beating the disease no longer means trading one kind of suffering for another.

Medical researcher in a lab examining vials related to asthma and COPD treatment and mRNA vaccine development, for article on benralizumab injection, for article on mRNA lung cancer vaccine

Injection beats steroids for asthma and COPD attacks in first major advance in 50 years

By / / Good News For Humankind

Asthma and COPD treatment may be on the verge of its biggest advance in 50 years, after a clinical trial found that a single injection of benralizumab outperformed standard steroid tablets for treating acute attacks. The study, published in Lancet Respiratory Medicine, showed four times fewer treatment failures at three months and 30% fewer follow-up interventions among patients receiving the injection. The trial targeted eosinophilic flare-ups, the biological subtype behind roughly half of all asthma attacks and nearly a third of COPD episodes. Together, the two conditions kill an estimated 3.8 million people annually, yet the standard of care has remained largely unchanged since the 1970s.

Breakthrough genomic test identifies virtually any infection in one go

By / / Good News For Humankind

A single lab test can now identify almost any pathogen — bacteria, virus, fungus, or parasite — from one patient sample, and it correctly pinpointed 86% of neurological infections in a trial of nearly 5,000 patients at UC San Francisco. The method, called metagenomic next-generation sequencing, screens cerebrospinal fluid against a library of more than 68,000 known pathogens and returns answers in about 48 hours, replacing weeks of educated guesswork with a clear picture of what’s actually there. An adapted version for respiratory samples could spot novel viral strains in 12 to 24 hours, offering an early warning system for future outbreaks. If deployed equitably, it could reshape how the world diagnoses infections and detects pandemics before they spread.

Close-up of a human eye with clear cornea, for an article about stem-cell cornea transplant research in Japan, for article on stem-cell cornea transplant

Japanese researchers restore sight with stem-cell cornea transplants in a world first

By / / Good News For Humankind

Stem-cell cornea transplants have been successfully performed on human patients for the first time, with Japanese surgeons using reprogrammed induced pluripotent stem cells to restore vision in three of four participants — results that held for more than a year. Published in The Lancet in 2024, the trial offers a potential path around the global shortage of donor corneal tissue, which currently leaves millions without treatment options. Corneal disease is among the leading causes of blindness worldwide, making a scalable alternative to donor transplants significant. While the trial was small, a 75% sustained success rate in a first-in-human study is a meaningful early result.

Wooden satellite, for article on wooden satellite

World’s first wooden satellite, developed in Japan, heads to space

By / / Good News For Humankind

LignoSat, a 10-centimeter cube of magnolia wood, is now circling Earth as the world’s first wooden satellite — a small experiment with big implications. Built by Kyoto University and Sumitomo Forestry, a company with 350 years of timber expertise, it was delivered to the International Space Station in November 2024. The idea is beautifully simple: when aluminum satellites burn up on reentry, they leave behind metallic particles drifting in the upper atmosphere, but wood combusts cleanly into carbon dioxide and water vapor. Magnolia samples tested in orbit held up without cracking or warping, surprising even the researchers. As tens of thousands more satellites prepare to launch this decade, LignoSat hints that the materials we send skyward matter as much as how we use them.

Salmon run, for article on Klamath dam removal, for article on Klamath River dam removal

Salmon return to Klamath River for first time in 112 years

By / / Good News For Humankind

Wild Chinook salmon have returned to the upper Klamath River for the first time since 1912, with biologists confirming the fish about 230 miles inland from the Pacific. The sighting came just months after the last of four dams was removed in summer 2024, completing the largest dam removal project in U.S. history. Klamath tribal members, who fought for decades to free the river, describe the salmon’s return as the homecoming of relatives. Biologists hope steelhead, coho, Pacific lamprey, and bull trout will follow. For rivers everywhere still bound by aging dams, one fish swimming home is a reminder that ecosystems can begin healing the moment we let them.

Blood cells under microscope, for article on smart insulin, for article on lab-grown blood cells

Danish scientists design new form of insulin that automatically switches itself on and off

By / / Good News For Humankind

Smart insulin that reads blood sugar in real time and adjusts its own activity has cleared a major hurdle in animal trials, according to Danish researchers publishing in Nature. The molecule switches on when glucose climbs and powers down as levels normalize, mimicking the feedback loop of a healthy pancreas. That matters because conventional insulin can overshoot and trigger dangerously low blood sugar, a side effect that endangers people living with diabetes every day. Scientists have chased this idea for more than 40 years, and earlier candidates kept stumbling in living bodies. For the more than 500 million people worldwide managing diabetes, an insulin that doses itself would be a quiet revolution — bringing daily care closer to how the body was meant to work.

Insulin pens, for article on duodenal mucosal resurfacing

New treatment eliminates insulin for 86% of patients in early trials

By / / Good News For Humankind

A one-hour outpatient procedure helped 12 of 14 Type 2 diabetes patients stop using insulin entirely and stay off it for a full year. Researchers at Amsterdam University Medical Center used a catheter to deliver gentle electrical pulses to the lining of the small intestine, prompting the tissue to regenerate and apparently restoring the body’s natural insulin response. By comparison, the widely used medication semaglutide alone helps only about one in five patients discontinue insulin. The team calls the approach “disease-modifying” because it targets the root cause rather than the symptoms, and a larger randomized trial is now in the works. If the results hold, it could reshape how a condition affecting hundreds of millions worldwide is treated.